3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Sarcoma
3
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Thyroid Neoplasms
8
Head and Neck Neoplasms
8
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Cancer, Papillary
6
Lung Neoplasms
6
Sarcoma
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Breast Neoplasms
5
Thyroid Diseases
4
Thoracic Neoplasms
4
Salivary Gland Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Neuroendocrine Tumors
4
Neoplasms by Site
4
Melanoma
4
Lung Diseases
4
Endocrine System Diseases
4
Endocrine Gland Neoplasms
4
Carcinoma, Bronchogenic
4
Bronchial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Nasopharyngeal Carcinoma
3
Glioma
3
Endometrial Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Medullary
3
Interventions
entrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Brain Neoplasms
×
Head & Neck
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA